Sean Maduck - 01 Dec 2025 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
Issuer symbol
CORT
Transactions as of
01 Dec 2025
Net transactions value
-$1,419,505
Form type
4
Filing time
03 Dec 2025, 20:53:43 UTC
Previous filing
05 Nov 2025
Next filing
13 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Maduck Sean Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck 03 Dec 2025 0001698310

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Options Exercise $165,400 +20,000 +253% $8.27 27,904 01 Dec 2025 Direct F1
transaction CORT Common Stock Sale $1,590,490 -20,000 -72% $79.52 7,904 01 Dec 2025 Direct F1, F2, F3
transaction CORT Common Stock Award $16,355 +205 +2.6% $79.78 8,109 01 Dec 2025 Direct F1, F4, F5
transaction CORT Common Stock Award $0 +205 +2.5% $0.000000 8,314 01 Dec 2025 Direct F1, F6
transaction CORT Common Stock Tax liability $10,770 -135 -1.6% $79.78 8,179 02 Dec 2025 Direct F1, F7, F8
holding CORT Common Stock 59,717 01 Dec 2025 See Footnote F9
holding CORT Common Stock 40,000 01 Dec 2025 See Footnote F10
holding CORT Common Stock 10,000 01 Dec 2025 See Footnote F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -20,000 -7.6% $0.000000 241,986 01 Dec 2025 Common Stock 20,000 $8.27 Direct F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2 This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.
F3 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.40 to $79.81 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025.
F5 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F6 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F7 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F8 The closing price on December 1, 2025 was used to calculate the withholding obligation.
F9 Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F10 Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F11 Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F12 Fully exercisable.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.